Padmanee Sharma and Jim Allison (MD Anderson)
February 23, 2023 06:28 AM ESTUpdated 06:56 AM
Deals
Bioregnum

For­mer high-fly­ing I/O biotech shelves lead drugs, chops staff and hands off the rem­nants in Nas­daq reshuf­fle

If there’s one les­son that shines through in the re­trench­ment go­ing on now in biotech, it’s that no great start­up sto­ry — re­gard­less of its dis­tin­guished …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times